Peapod Lane Capital’s Metagenomi Therapeutics MGX Stock Holding History

Peapod Lane Capital’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$625K	Buy	525,024 +8,263	+2%	+$11.1K	0.42%	60
2026 Q1	$683K	Buy	516,761 +19,108	+4%	+$29.7K	0.56%	58
2025 Q4	$806K	Sell	497,653 -16,162	-3%	-$35K	0.69%	50
2025 Q3	$1.22M	Buy	513,815 +5,706	+1%	+$11.6K	1.09%	42
2025 Q2	$752K	Buy	508,109 +155,652	+44%	+$244K	0.75%	47
2025 Q1	$479K	Buy	352,457 +1,244	+0.4%	+$2.96K	0.54%	55
2024 Q4	$1.27M	Buy	+351,213	New	+$847K	1.26%	34

Other funds holding MGX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Peapod Lane Capital's MGX Position: Q2 2026 in Review

Peapod Lane Capital increased its Metagenomi Therapeutics (MGX) stake by 1.6% in Q2 2026, buying an estimated $11.1K and bringing the position to 525,024 shares worth $625K. The position accounts for 0.42% of the portfolio, ranked #60.

Peapod Lane Capital first reported a position in MGX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.27M in Q4 2024. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

Peapod Lane Capital held 525,024 shares of Metagenomi Therapeutics worth $625K as of Q2 2026.
Peapod Lane Capital bought 8,263 Metagenomi Therapeutics shares in Q2 2026, an estimated $11.1K.
Metagenomi Therapeutics made up 0.42% of Peapod Lane Capital's portfolio in Q2 2026, its #60 holding.
Peapod Lane Capital first reported a position in Metagenomi Therapeutics in Q4 2024 and has held it in 7 quarters since.
Peapod Lane Capital's Metagenomi Therapeutics position peaked at $1.27M in Q4 2024.
43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Peapod Lane Capital's 13F filing for Q2 2026, filed 27 Jul 2026.